Roth brings nearly three decades of leadership experience across corporate finance, strategy, financial transformation, and fundraising to NTx. She held CFO and senior finance consultant roles at several venture capital and investment firms in the U.S., such as Alchemy Ventures and CaBo Capital, along with several firms in Istanbul, Turkey, such as Hitay Holding, and Eczacıbası Group, one of the top three international conglomerates in Turkey. While at Eczacıbası Group, she also initiated a new venture for the firm in a B2B industry and led it to become an industry leader within its geographic markets.
Earlier in her career, she also held VP level roles at Citibank in Turkey and served as a director of corporate strategy at Turk Telekom, a multi-billion-dollar telecommunications company, and led the strategy function to bring the formerly government owned monopoly to adjust to free-market and prepare for its successful IPO. Roth holds a BA in Economics and Computer Science from Smith College and an MA in International Economics and Finance from Brandeis University.
“Ms. Roth brings a unique, diverse set of leadership skills, not just within finance, but across many critical aspects of business from her time working with startups and in the venture capital world,” said Alex Koglin, co-founder and CEO at NTx. “Her ability to build effective and robust financial accounting and reporting infrastructure, along with her savvy investor relations experience will help scale the company.”
“NTx has developed a truly novel platform that can transform the way life-saving therapeutics are manufactured,” said Yesim Roth. “I am thrilled to be joining this brilliant leadership team and am looking forward to building financial and operational processes that can take this company and its technology to the next level.”
For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com.
Nature’s Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico. The company is commercializing its biomanufacturing systems NTxpress®, NTxscribe® and the bioinformatics platform, DruID, for the discovery of natural products. NTx’s proprietary continuous-flow, fully recombinant, in vitro, cell-free transcription system utilizes hollow fiber bioreactors to support the growing demand for mRNA-based vaccines and therapeutics. NTx’s biomanufacturing processes can easily be scaled to meet fluctuating supply needs so that companies can increase and streamline production as they respond to changing global demands. For more information, please visit: https://www.ntxbio.com.
Kalyn Kolek, firstname.lastname@example.org